Developer docs
API playgroundTry for free, no card

Search company profiles

Stem Cell Therapeutics

Full company profile

uuid003ixiz

Namestring
Stem Cell Therapeutics
Websiteurl
stemcellthera.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Stem Cell Therapeutics is a Toronto, Canada-based, publicly traded biopharmaceutical development company (TSX: SSS) founded in 2004. According to the firm's own short description, it is engaged in the discovery of cancer stem cell (CSC)-related biology intended to underpin novel cancer therapies, placing it in the early-stage oncology drug discovery segment. The company operates with a small headcount of 11-50 employees and maintains a publicly disclosed C-suite including a CEO (Niclas Stiernholm), CFO (James Parsons), and CSO (Bob Uger), indicating a research-oriented organizational design typical of pre-clinical or early-clinical biotechs.

The company's capital structure reflects a clinical-stage biotech profile: it completed a $33,000,000 financing round in December 2013 with participation from a specialized syndicate of biotech-focused investors including HSMR Advisors, Merlin Nexus, Ridgeback Capital, Sabby Capital, Special Situations Funds, and venBio Partners. No products, licensing deals, clinical milestones, partnerships, patents, or revenue figures are disclosed in the available source material, and the company's web domain (stemcellthera.com) currently resolves to unrelated Indonesian government anti-gambling campaign content (KOMDIGI document SE-27/KOMDIGI/07/2026), suggesting the corporate web presence is not actively maintained or has been displaced.

Given the absence of disclosed commercial products, customer relationships, pricing, or partnership arrangements, no revenue model or go-to-market motion can be described from the evidence. The company's economic engine — to the extent one exists — is most likely capital-markets-driven (equity raises and potentially grant funding) rather than product sales, consistent with a discovery-stage oncology biotech awaiting preclinical or clinical catalysts that are not documented in the source data.

Short descriptiontext

Stem Cell Therapeutics is a Toronto-based, TSX-listed (SSS) early-stage biopharmaceutical company founded in 2004 that focuses on cancer stem cell discoveries intended to underpin novel cancer therapies for oncology indications.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersToronto, Canada
HQ citystring
Toronto
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cancer stem cell therapy, biopharmaceutical development, oncology drug discovery, stem cell therapeutics, hematologic cancer research
Industry2 codes
1Stem Cell Therapies (MSC/iPSC/HSC-derived)
CodeHLAAABAEPrimaryYes
2Stem Cell–Based Regenerative Therapies
CodeHLAAAGAAPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical R&D
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Stem Cell Therapeutics is a biopharmaceutical development company focused on discovering and developing therapeutics based on cancer stem cell biology for the treatment of cancer. The company engages in cancer stem cell research intended to inform the development of novel oncology therapies targeting cancer-initiating cell populations.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Cancer Stem Cell Therapeutics Program
CategoryOncology Drug Discovery
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Mesoblast
TypeDirect peer
Description

Public cell therapy company developing mesenchymal stem cell-derived therapeutics, comparable as a publicly listed small-cap biotech advancing stem cell-based therapies into the clinic.

2MEI Pharma
TypeBroad incumbent
Description

Clinical-stage oncology company developing differentiated therapies for cancer. Comparable as a small public oncology biotech with similar capital-raising dynamics, although not specifically cancer stem cell-focused.

3OncoMed Pharmaceuticals
TypeDirect peer
Description

Pioneered the cancer stem cell therapeutic concept with antibody and biologic programmes targeting Wnt, Notch, and other CSC pathways. Direct peer even though assets have since been wound down or out-licensed, providing the most direct comparability in mechanism and historical valuation pattern.

4Pluristem Therapeutics
TypeDirect peer
Description

Public cell therapy company developing placenta-derived stem cell products. Comparable as a small public stem cell therapy company with similar headcount and capital constraints.

5Capricor Therapeutics
TypeEmerging player
Description

Clinical-stage biotech developing cell therapy approaches (e.g. CAP-1002 allogeneic cardiosphere-derived cells). Comparable as a small-cap public cell therapy developer, though therapeutic area differs.

6Cellerant Therapeutics
TypeEmerging player
Description

Private clinical-stage company developing antibody and cellular therapies that target cancer stem cells. Comparable mechanism and stage, although private rather than public.

7Athersys
TypeDirect peer
Description

Public clinical-stage biotech developing MultiStem cell therapy across multiple indications. Comparable as a small-cap public stem cell therapy developer with similar capital structure dynamics.

8Stemcentrx
TypeDirect peer
Description

Developed antibody-drug conjugates directed at cancer stem cell antigens (e.g. rovalpituzumab tesirine) and was acquired by AbbVie for up to $5.8B. Comparable as a cancer stem cell-focused clinical biotech.

9Stemline Therapeutics
TypeBroad incumbent
Description

Commercial-stage oncology company developing novel therapeutics including those targeting cancer stem cell pathways, acquired by the Menarini Group. Comparable as an oncology biotech with cancer stem cell connections and as an exit-case reference for small public peers.

10Verastem
TypeDirect peer
Description

Clinical-stage oncology company developing therapeutics that target cancer stem cell pathways (e.g. focal adhesion kinase inhibitors). Highly comparable as a small public biotech with a cancer stem cell-directed mechanism.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stem Cell Therapeutics

Biopharmaceutical R&Dstemcellthera.com

Stem Cell Therapeutics is a Toronto-based, TSX-listed (SSS) early-stage biopharmaceutical company founded in 2004 that focuses on cancer stem cell discoveries intended to underpin novel cancer therapies for oncology indications.

What Stem Cell Therapeutics does

Stem Cell Therapeutics is a Toronto, Canada-based, publicly traded biopharmaceutical development company (TSX: SSS) founded in 2004. According to the firm's own short description, it is engaged in the discovery of cancer stem cell (CSC)-related biology intended to underpin novel cancer therapies, placing it in the early-stage oncology drug discovery segment. The company operates with a small headcount of 11-50 employees and maintains a publicly disclosed C-suite including a CEO (Niclas Stiernholm), CFO (James Parsons), and CSO (Bob Uger), indicating a research-oriented organizational design typical of pre-clinical or early-clinical biotechs.

The company's capital structure reflects a clinical-stage biotech profile: it completed a $33,000,000 financing round in December 2013 with participation from a specialized syndicate of biotech-focused investors including HSMR Advisors, Merlin Nexus, Ridgeback Capital, Sabby Capital, Special Situations Funds, and venBio Partners. No products, licensing deals, clinical milestones, partnerships, patents, or revenue figures are disclosed in the available source material, and the company's web domain (stemcellthera.com) currently resolves to unrelated Indonesian government anti-gambling campaign content (KOMDIGI document SE-27/KOMDIGI/07/2026), suggesting the corporate web presence is not actively maintained or has been displaced.

Given the absence of disclosed commercial products, customer relationships, pricing, or partnership arrangements, no revenue model or go-to-market motion can be described from the evidence. The company's economic engine — to the extent one exists — is most likely capital-markets-driven (equity raises and potentially grant funding) rather than product sales, consistent with a discovery-stage oncology biotech awaiting preclinical or clinical catalysts that are not documented in the source data.

Stem Cell Therapeutics firmographics

Firmographics
Name
Stem Cell Therapeutics
Website
https://stemcellthera.com
Company type
Private
Founded year
2004
Headcount range
11–50 employees
Short description
Stem Cell Therapeutics is a Toronto-based, TSX-listed (SSS) early-stage biopharmaceutical company founded in 2004 that focuses on cancer stem cell discoveries intended to underpin novel cancer therapies for oncology indications.
Ownership category
akta.pro rank

Stem Cell Therapeutics industry classification

Industry
Product category
Biopharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro primary industry
Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
akta.pro secondary industry
Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

  • Cancer stem cell therapy
  • Biopharmaceutical development
  • Oncology drug discovery
  • Stem cell therapeutics
  • Hematologic cancer research

Where Stem Cell Therapeutics is headquartered

Location

Headquarters

HQ city
Toronto
HQ country
Canada
HQ region
North America

Markets served

Stem Cell Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Stem Cell Therapeutics product offering

Product offering

Core offering

Stem Cell Therapeutics is a biopharmaceutical development company focused on discovering and developing therapeutics based on cancer stem cell biology for the treatment of cancer. The company engages in cancer stem cell research intended to inform the development of novel oncology therapies targeting cancer-initiating cell populations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cancer Stem Cell Therapeutics Program

Companies that use Stem Cell Therapeutics

Customer profile

Ideal customer profiles1 record

Stem Cell Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stem Cell Therapeutics partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Stem Cell Therapeutics competitors and assessment

Company assessment

Direct peers

  • Mesoblast: Public cell therapy company developing mesenchymal stem cell-derived therapeutics, comparable as a publicly listed small-cap biotech advancing stem cell-based therapies into the clinic.
  • OncoMed Pharmaceuticals: Pioneered the cancer stem cell therapeutic concept with antibody and biologic programmes targeting Wnt, Notch, and other CSC pathways. Direct peer even though assets have since been wound down or out-licensed, providing the most direct comparability in mechanism and historical valuation pattern.
  • Pluristem Therapeutics: Public cell therapy company developing placenta-derived stem cell products. Comparable as a small public stem cell therapy company with similar headcount and capital constraints.
  • Athersys: Public clinical-stage biotech developing MultiStem cell therapy across multiple indications. Comparable as a small-cap public stem cell therapy developer with similar capital structure dynamics.
  • Stemcentrx: Developed antibody-drug conjugates directed at cancer stem cell antigens (e.g. rovalpituzumab tesirine) and was acquired by AbbVie for up to $5.8B. Comparable as a cancer stem cell-focused clinical biotech.
  • Verastem: Clinical-stage oncology company developing therapeutics that target cancer stem cell pathways (e.g. focal adhesion kinase inhibitors). Highly comparable as a small public biotech with a cancer stem cell-directed mechanism.

Broad incumbents

  • MEI Pharma: Clinical-stage oncology company developing differentiated therapies for cancer. Comparable as a small public oncology biotech with similar capital-raising dynamics, although not specifically cancer stem cell-focused.
  • Stemline Therapeutics: Commercial-stage oncology company developing novel therapeutics including those targeting cancer stem cell pathways, acquired by the Menarini Group. Comparable as an oncology biotech with cancer stem cell connections and as an exit-case reference for small public peers.

Emerging players

  • Capricor Therapeutics: Clinical-stage biotech developing cell therapy approaches (e.g. CAP-1002 allogeneic cardiosphere-derived cells). Comparable as a small-cap public cell therapy developer, though therapeutic area differs.
  • Cellerant Therapeutics: Private clinical-stage company developing antibody and cellular therapies that target cancer stem cells. Comparable mechanism and stage, although private rather than public.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Stem Cell Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stem Cell Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

Stem Cell Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stem Cell Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stem Cell Therapeutics

What does Stem Cell Therapeutics do?

Stem Cell Therapeutics is a biopharmaceutical development company focused on discovering and developing therapeutics based on cancer stem cell biology for the treatment of cancer. The company engages in cancer stem cell research intended to inform the development of novel oncology therapies targeting cancer-initiating cell populations.

When was Stem Cell Therapeutics founded?

Stem Cell Therapeutics was founded in 2004. It employs 11 to 50 people.

Where is Stem Cell Therapeutics based?

Stem Cell Therapeutics is headquartered in Toronto, Canada, in the North America region.

Who are Stem Cell Therapeutics's main competitors?

Direct peers on record are Mesoblast, OncoMed Pharmaceuticals, Pluristem Therapeutics, Athersys, Stemcentrx and Verastem. Broad incumbents are MEI Pharma and Stemline Therapeutics. Emerging players are Capricor Therapeutics and Cellerant Therapeutics.

Does Stem Cell Therapeutics have an API?

No public API is recorded for Stem Cell Therapeutics.

What industry is Stem Cell Therapeutics in?

Stem Cell Therapeutics's product category is Biopharmaceutical R&D. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireStem Cell Therapeutics Changes Its Name to Trillium Therapeutics Inc.Stem Cell Therapeutics Corp. filed articles of amalgamation to merge with its subsidiary Trillium Therapeutics Inc., adopting the Trillium name. The combined company will trade under the symbol "TR" and focuses on immuno-oncology, including a CD47/SIRPa checkpoint inhibitor program.GlobeNewswireStem Cell Therapeutics Graduates to the Toronto Stock ExchangeStem Cell Therapeutics Corp. will list its common shares on the Toronto Stock Exchange on April 22, 2014, under the symbol SSS. The company granted options to purchase 7,923,868 shares at $0.345 each to executive officers. The listing is expected to improve access to capital markets.GlobeNewswireStem Cell Therapeutics Provides Corporate UpdateStem Cell Therapeutics completed six-month primate tolerability studies for its SIRPaFc CD47 antagonist, establishing safe dosing levels. The company also completed a $33 million private placement to fund development. It will amplify preclinical efficacy studies and expects the Phase I AML trial to finish in 2014.GlobeNewswireStem Cell Therapeutics Provides Corporate UpdateStem Cell Therapeutics expects safety and pharmacokinetic data from its CD47 antagonist studies in rodents and non-human primates in the third quarter. A Phase I study with tigecycline in AML patients is also expected to complete in Q3, guiding a Phase II trial projected for 2014.GlobeNewswireStem Cell Therapeutics Completes Trillium Merger and Issues Stock OptionsStem Cell Therapeutics completed its merger with Trillium Therapeutics, with Trillium shareholders voting overwhelmingly in favor. The company issued 2,560,197 stock options at $0.25 with a ten-year term to directors, officers, and employees. The issuance is subject to TSX Venture exchange acceptance.GlobeNewswireStem Cell Therapeutics Provides Corporate Update on Acquisitions and FinancingStem Cell Therapeutics signed a definitive merger agreement with Trillium Therapeutics, with debenture holders converting to common shares and holding a two-thirds majority. The closing date was extended to accommodate the April 5 shareholder meeting. The company also closed its U.S. private placement, bringing total financing proceeds to $3,185,080.GlobeNewswireStem Cell Therapeutics Closes $3.1 Million FinancingStem Cell Therapeutics closed a prospectus offering of 12,315,000 units at $0.25 each, raising $3,078,750. The funds will support the acquisition of Trillium Therapeutics and a license to Tigecycline intellectual property. The company aims to advance its cancer stem cell therapeutic development.GlobeNewswireStem Cell Therapeutics Annual General MeetingStem Cell Therapeutics Corp. announced its annual general meeting and corporate update will be held on July 18, 2012, at 4:00 p.m. ET in Toronto. Shareholders unable to attend can join via conference call, with a Q&A session led by Executive Chairman David Allan. The company's NTx-428 product is in a Phase II clinical trial.GlobeNewswireStem Cell Therapeutics Corp. Provides Corporate UpdateStem Cell Therapeutics Corp. announced its 2011 fourth quarter and year-end financial results will be released on or about April 26, 2012, followed by a conference call on April 27. The call will be hosted by Executive Chairman David Allan, with details to be confirmed in the financial press release.GlobeNewswireStem Cell Therapeutics Announces Reorganization and Management ChangesStem Cell Therapeutics announced a corporate reorganization to reposition as a commercialization partner for stem cell technologies, recruiting Dr. Albert Agro as Chief Medical Officer and others. The company will make a provision of approximately $141,000 for termination payments in Q4 and expects net savings by end of 2012.